Kevin Kalinsky, MD, MS

Kevin Kalinsky, MD, MS, is a professor and director of the Division of Medical Oncology in the Department of Hematology and Medical Oncology at Emory University School of Medicine; and the Louisa and Rand Glenn Family Chair in Breast Cancer Research and director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University in Atlanta, Georgia.

Articles

Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO

November 7th 2025

Dr Kalinsky discusses the treatment paradigm for HR-positive breast cancer post-CDK4/6 inhibition and the need for therapeutic advances in this setting.

Dr Kalinsky on the Importance of Novel Second-Line Therapies for HR+ Breast Cancer

November 5th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses research needs to improve treatment strategies in the post-CDK4/6 inhibitor setting for HR-positive breast cancer.

Identifying Unmet Needs and Remaining Questions

October 3rd 2025

Panelists discuss how the rapidly evolving breast cancer treatment landscape includes promising developments in oral selective estrogen receptor degraders (SERDs), CDK4/6 inhibitor sequencing strategies, and antibody-drug conjugates (ADCs), with new targeted therapies and bispecifics continuing to emerge.

Treatment Options in the 2L for HER2-Low Disease Including ADCs and Endocrine Therapy

October 2nd 2025

Panelists discuss how treatment decisions between antibody-drug conjugates (ADCs) and continued endocrine-based therapies in HER2-low disease depend on endocrine sensitivity, with ADCs reserved for endocrine-refractory tumors or primary endocrine-resistant cases with short initial response durations.

Evaluating the ASCENT-04 Trial Results in Triple-Negative Disease

October 2nd 2025

Panelists discuss how the ASCENT-04 trial findings establish sacituzumab govitecan (SG)plus pembrolizumab as an active standard-of-care combination for triple-negative breast cancer, with considerations needed for patients with prior immunotherapy exposure.

The Role of T-DXd in the Frontline Setting for HER2+ mBC and Treatment Personalization

October 1st 2025

Panelists discuss how DESTINY-Breast09 data support trastuzumab deruxtecan (T-DXd) plus pertuzumab in frontline HER2-positive disease for select patients with extensive disease or brain metastases while emphasizing individualized treatment decisions to avoid overtreatment.

CDK4/6 Inhibitor Sequencing in the Metastatic Setting and Maintenance Strategies Following THP Induction

October 1st 2025

Panelists discuss how prior adjuvant CDK4/6 inhibitor exposure complicates metastatic treatment decisions, with limited data supporting rechallenge strategies and the need for more targeted therapies such as CDK2- or CDK4-specific inhibitors.

CDK4/6 Inhibitor Combination Therapy in HER2+ Disease

September 24th 2025

Panelists discuss how the PATINA trial findings demonstrate significant progression-free survival benefit from adding palbociclib to endocrine and HER2-targeted therapy in patients with estrogen receptor (ER)–positive, HER2-positive disease following induction chemotherapy, though access challenges remain in clinical practice.

Considering the Oral SERD and PROTAC Toxicity Profiles

September 24th 2025

Panelists discuss how the well-tolerated safety profiles of oral selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs), despite some low-grade toxicities such as bradycardia and photopsia, make them attractive options, with treatment decisions potentially influenced by specific adverse effect considerations and monitoring requirements.

Combination Treatment Options for Patients With ESR1 Mutation and Comutations

September 17th 2025

Panelists discuss how treatment approaches for patients with both ESR1 mutations and PI3K pathway alterations currently rely on single-agent elacestrant for slow-growing disease or doublet therapies for more aggressive cases, with the field rapidly evolving toward targeted combination therapies.

Emerging Oral SERD and PROTAC Treatment Options as Monotherapy and in Combination

September 17th 2025

Panelists discuss how proteolysis-targeting chimera (PROTAC) agents such as vepdegestrant offer a different mechanism of action compared with oral selective estrogen receptor degrader (SERDs), with promising clinical activity in ESR1-mutant tumors and the need for more data on optimal sequencing strategies.

Evaluating Longitudinal ctDNA Testing for Molecular Progression During CDK4/6 Inhibitor Therapy

September 8th 2025

Panelists discuss how longitudinal surveillance testing could enable treatment interventions based on molecular progression (ESR1 mutations) rather than waiting for radiographic progression, though questions remain about overall survival impact.

The Impact of Oral SERDs on the Changing Treatment Landscape

September 8th 2025

Panelists discuss how oral selective estrogen receptor degraders (SERDs) such as elacestrant are changing treatment for patients experiencing progression on CDK4/6 inhibitors, with current approval for ESR1-mutant tumors and anticipation of additional approvals for other oral SERDs in development.

Dr Kalinsky on Evolving Roles for the CLEOPATRA and DESTINY-Breast09 Regimens in HER2+ Breast Cancer

June 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses potential new roles for the CLEOPATRA and DESTINY-Breast09 regimens in the HER2-positive breast cancer paradigm.

Dr Kalinsky on the Importance of Biomarker Testing in HR+/HER2-Negative Advanced Breast Cancer

June 10th 2025

Kevin Kalinsky, MD, discusses the importance of biomarker testing in guiding therapeutic decision-making in HR-positive, HER2-negative breast cancer.

Dr Kalinsky on Efficacy Data From SERENA-6 in ER+/HER2– Advanced Breast Cancer

June 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses data with camizestrant plus a CDK4/6 inhibitor in ER–positive, HER2-negative advanced breast cancer.

Dr Kalinsky on the Potential to Switch CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

March 8th 2025

Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.

Summary of Recent Advances and Unmet Needs for Patients With eBC

December 25th 2024

Panelists discuss key updates from the past year regarding HR+/HER2– early breast cancer (eBC), emerging research that could transform treatment approaches, and the role of new biomarkers in patient identification, stratification, and predicting CDK4/6 inhibitor responses; they also highlight studies on the horizon that may further refine treatment strategies and offer closing clinical pearls for diagnosing and managing early-stage breast cancer.

Multidisciplinary Treatment Sequencing and Coordination

December 25th 2024

Panelists discuss their approach to sequencing surgery, radiation, and systemic therapies for early-stage breast cancer patients, emphasizing the guiding principles of treatment sequencing and how individual patient factors influence decisions; they also highlight the importance of multidisciplinary coordination, identifying key specialists, ensuring alignment on diagnosis, risk assessment, and treatment goals, and the critical role of including the patient in these discussions.

Managing CDK4/6 Inhibitor Toxicities and Encouraging Adherence

December 18th 2024

Panelists discuss how common adverse events (AEs) with CDK4/6 inhibitors in HR+/HER2- early breast cancer (eBC) vary based on treatment and patient population, with strategies for mitigating toxicities, adjusting dosing, and monitoring labs to ensure treatment continuation; they also address approaches to dose reductions, promoting treatment adherence, educating patients about toxicity management, and balancing efficacy, quality of life, and side effect risks, particularly for high-risk patients with no or low nodal involvement.